CliffBio
small molecule

SOAANZ

TORSEMIDE

Loss of exclusivity—loss of exclusivity
CompanySarfez Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameSOAANZ
Active ingredientTORSEMIDE
Strength40MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2021
Marketing statusRX

More from Sarfez Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

SOAANZ patent cliff — loss of exclusivity — | CliffBio